

Figure S1




Figure S2




Figure S3





Figure S4




Figure S5





Table S1. The binding kinetics of ibalizumab and its LMs to human CD4

Antibody	$K_{on}$ ( $10^5/Ms$ )	$K_{off}$ ( $10^{-5}/s$ )	$K_D$ (0.1 nM)
ibalizumab	2.8	12	4.3
LM30E	1.1	15	14
LM52	4.6	16	3.5
LM53	2.9	13	4.5
LM54	3.7	27	7.3
LM60	4.4	8.3	1.9
LM65	3.3	49	15
LM67	2.5	20	8
LM76	5.0	14	2.8

Table S2. Comparison of ibalizumab and its light chain mutants

	WT	LM30E	LM52	LM53	LM54	LM65	LM67	LM60	LM76
Mean MPI (%)	75	<b>98</b>	<b>98</b>	<b>99</b>	<b>93</b>	<b>93</b>	<b>91</b>	75	78
Distance (Å) to V5		<b>11.1</b>	<b>19.8</b>	<b>19.8</b>	<b>23.3</b>	<b>21.3</b>	<b>18.9</b>	27.6	31.2
IC <sub>80</sub> (µg/mL) Geometric mean	0.87	<b>0.14</b>	<b>0.05</b>	<b>0.09</b>	<b>0.28</b>	<b>0.20</b>	<b>0.05</b>	1.5	0.75

Table S4. Comparison of the IC<sub>80</sub>(µg/mL) of ibalizumab and its single, double, and triple LMs

Virus	ibalizumab	LM52	LM30E-53	LM30E-52	LM52-67	LM30E-53-67	LM30E-52-67
RHPA4259	>10	0.03	0.02	0.10	0.02	0.06	0.23
SHIVsf162P3	>10	0.37	0.32	0.61	0.37	0.68	0.89
SHIVsf162P3N	>10	>10	0.93	4.40	0.98	4.40	2.50
9015-07 A1	0.24	0.04	0.04	0.06	0.04	0.08	0.13
1051-D927 TD12	>10	0.04	0.05	0.09	0.04	0.20	0.32
Q769.d22	>10	0.13	0.15	0.29	0.11	0.47	0.49
16055-2.3	>10	0.04	0.06	0.08	0.05	0.13	0.24
246F C1G C	>10	0.07	0.10	0.22	0.02	0.30	0.49
QG393.60M	>10	0.05	0.05	0.07	0.04	0.10	0.11
ZM249M.PL1	0.22	0.05	0.06	0.12	0.05	0.10	0.13
Q259.d2.17	0.37	0.09	0.10	0.15	0.07	0.13	0.26
Q461.e2	0.61	0.09	0.10	0.14	0.09	0.16	0.18
Geometric Mean	3.20	0.10	0.09	0.18	0.07	0.22	0.31